Mandate

Vinge has advised Tobii AB (publ) in connection with its rights issue

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary shares which will provide Tobii with issue proceeds of approximately SEK 301 million before deduction of transaction costs.

The new ordinary shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 15 April 2024. Tobii develops technology within eye tracking and attention computing which understands human attention and intent. Tobii’s eye tracking solutions are used by thousands of enterprises, universities and research institutes around the globe. The company's ordinary shares are listed on Nasdaq Stockholm.

 

Vinge’s team consisted primarily of Jesper Schönbeck, Rikard Lindahl, Amanda Knutsson, Joel Magnusson, Oskar Nilsson, Lorin Arabi, Elias Kröger, Lovisa Jonassen och William Carlberg Johansson.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024